Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial

Authors

Institutions

Publication Details

Journal
The Lancet Neurology
Published
2024-09-19
DOI
https://doi.org/10.1016/s1474-4422(24)00320-x
Citations
13
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
3.49

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial

Vinojini Vivekanandam, Michael G. Hanna, Richard J. Barohn, Michael McDermott et al.
13 citations
The Lancet Neurology
Genetic Neurodegenerative Diseases
3.49
article

Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial

Vinojini Vivekanandam, Michael G. Hanna, Richard J. Barohn, Michael McDermott, Iwona Skorupinska, Emma Matthews, Dipa Jayaseelan
article en
13 citations

Abstract

No abstract available for this paper.
The Lancet NeurologyVol. 23(10)
St George's, University of London (GB), University of Rochester Medical Center (US), National Hospital for Neurology and Neurosurgery (GB), University College London (GB), University of Missouri (US)
Medical Research Council
Gender equality
Openalex Percentile: Top 7%
Genetic Neurodegenerative Diseases
3.49
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.